Zolpharm 4 Injection

Description of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

Zoledronic acid is an active substance of Zolpharm 4mg injection, which acts as an antineoplastic and anti-resorptive, which is a member of the bisphosphonate family. The use is mainly mentioned in the prevention and treatment of bone complications in cancer patients, especially those with metastases on the bones. The pharmacologic action is done by inhibiting osteoclast-mediated bone resorption, resulting in the increase in bone strength, and the rate of bone fracture is slowed down. Zoledronic acid is also used in the management of hypercalcaemia of malignancy whereby the cause of high calcium level is as a result of the occurrence of neoplastic disease. It is administered intravenously, and the duration of action is very long.

Indications of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

Zoledronic acid is used in the treatment setting of: Bone metastases in cancer, Hypocalcaemia of malignancy, hypercalcaemia of malignancy, Gut malignancies, and Multiple myeloma 

Mechanism of action of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

The agent inhibits osteoclasts by blocking the mevalonate pathway which is an essential biochemical pathway to osteoclast activity. This results in bone resorption deceleration and stabilisation of skeletal structure. The decrease in the bone calcium release also contributes to the management of hypercalcaemia. All of these functions reduce bone complications and enhance bone strength.

How to consume Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

The administration is done through intravenous infusion over a specific period of time usually under the care of a medical professional. The dosage and frequency depend upon the indication. It is advisable that sufficient hydration should be done prior to infusion to reduce the risk of renal adverse effects.

Side Effects of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

1. Common side effects

• Fever
• Fatigue
• Bone pain
• Nausea
• Headache

2. Serious side effects

• Renal toxicity
• Hypocalcemia
• Osteonecrosis of jaw
• Severe allergic reactions

3. Rare side effects

• Atypical fractures
• Cardiac arrhythmias

Safety Advice for Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

Individuals receiving zoledronic acid are to be carefully monitored in terms of renal activity and serum calcium levels due to the fact that the medication in question can significantly deteriorate renal functioning and disrupt mineral balance. The hydration before and after the infusion is not only necessary to reduce the chances of nephrotoxicity.

Breastfeeding: Zoledronic acid should not be given during lactation because the drug can enter through breast milk and negatively affect the bone formation of the foetus.

Pregnancy: The medication should not be used during pregnancy because of the ability to disrupt the formation of foetal osteogenesis and trigger skeletal defects.

Alcohol: Alcohol intake needs to be limited because alcohol increases dehydration and increases the likelihood of renal damage and electrolyte imbalance.

Liver: Despite bone and kidney being the major targets of zoledric acid, patients with liver dysfunction need to be closely monitored, as there are chances of changing metabolism and tolerance levels.

Lungs: Any arising conditions like dyspnea or hypersensitivity reaction during infusion should be immediately recorded as infusion-related reaction may occur.

Kidney: Renal function has to be checked before every dose, as zoledronic acid may cause acute kidney failure especially in dehydrated or high-risk patients.

Driving: Patients are likely to experience the following effects after infusion; vertigo, fatigue and flu-like symptoms; thus, driving should be avoided until this passes.

Interaction of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

• Drug–Drug Interaction

Aminoglycosides × Zoledronic acid

Aminoglycosides and zoledronic acid can be considered a combination that leads to a severe outcome in terms of hypocalcemia; therefore, the electrolyte levels should be monitored carefully.

Loop diuretics × Zoledronic acid. 

The interactions of loop diuretics and zoledronic acid can lead to more risks of dehydration and electrolyte imbalance that can aggravate renal dysfunction.

Nephrotoxic medication (e.g., NSAIDs, cisplatin) × Zoledronic acid 

Coadministration of nephrotoxic drugs and zoledronic acid significantly increases the risk of renal toxicity because the two drugs are capable of undermining kidney activity.

Corticosteroids × Zoledronic acid. 

Zoledronic acid together with long-term corticosteroid treatment could lead to higher rates of osteonecrosis of the jaw, particularly in patients with cancer who have dental treatment.

Other bisphosphonates × Zoledronic acid. 

Two or more bisphosphonates are not normally combined due to the lack of proportionate effects between cumulative toxicity and therapeutic effects.

• Drug–Food Interaction 

Zoledronic acid is taken in form of an intravenous and hence, food does not influence the pharmacokinetics of the drug. Nevertheless, in order to have normal mineral balance in the treatment process, sufficient calcium and vitamin D should be taken.

• Drug–Disease Interaction of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

Kidney disease:
Dose reduction and strict care are necessary to avoid acute kidney failure.

Hypocalcemia: 

The medication also reduces calcium levels; patients who come in with hypocalcemia should be corrected before any treatment starts in order to prevent other complications like muscular cramping, or cardiac arrhythmias.

Dental disorders: 

Poor oral health patients or patients receiving dental care are at high risk of developing osteonecrosis of the jaw that is an extreme side effect of bisphosphonate treatment.

Dehydration: 

Dehydrated patients are also likely to be affected by the effect of renal damage and in such cases, the patient should be well hydrated prior to administration.

Contraindication of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

Hypersensitivity, severe severity of renal failure, hypocalcemia, and pregnancy are contraindications of the agent.

Dosage of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

The dosage is 4 mg that is normally administered intravenously, although dosing intervals vary according to clinical indication. Adjustment of dose may be required depending on adjustments of renal functioning.

Storage of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

Goods are not to be stored under the conditions that are recommended by the store, but in the inaccessibility of children.

Missed Dose of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

When one dose is missed, one should take it as soon as possible under the advice of the medical expert.

Other General Information of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

During treatment the patients should be well hydrated and rich in calcium. It is essential to review regularly to cheque the renal function and identify adverse effects at an early stage.

FAQs of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

1. What is the purpose of administering zoledronic acid to patients who have bone metastasis of cancer?

Zoledronic acid causes a decrease in bone resorption, fractures, and risk of skeletal complications of malignancy.

2. Is the zoledronic acid toxic to the kidneys?

Yes, especially when used rapidly or in the case of dehydrated patients therefore, renal functioning should be observed before the administration of each dose.

3. Why is the monitoring of calcium significant?

Since zoledronic acid blocks the calcium liberation in the bone, the outcomeant hypocalcemia causes further complications unless attention is closely monitored.

4. What is the reason why a dental cheque-up is advisable prior to treatment?

It is the pre-treatment dental appraisal that helps in reducing the risk of osteonecrosis of the jaw that is one of the possible adverse effects of the use of bisphosphonates.

5. What are the precautions in case of infusion?

Patients are advised to be fully hydrated and the infusion needs to be gradual under the presence of a doctor to reduce any undesirable effects.

Fact Box of Zolpharm 4 mg (Zoledronic Acid 4 mg) injection

References

• FDA Prescribing Information – Zolpharm (Zoledronic acid)
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021223s043lbl.pdf
• European Medicines Agency (EMA) – Zoledronic acid Product Information
  https://www.ema.europa.eu/en/documents/product-information/Zolpharm-epar-product-information_en.pdf
• DrugBank – Zoledronic acid
  https://go.drugbank.com/drugs/DB00399
• National Cancer Institute (NCI) – Zoledronic acid
  https://www.cancer.gov/about-cancer/treatment/drugs/zoledronic-acid